Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Tenax Therapeutics, Inc.NASDAQ: TENX
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $2K, compared with $0 a year earlier. Over 3 fiscal years it compounded at -39.8% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 1K USD
- Year-over-year change
- —
- 4-year CAGR
- -20.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1K | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 30 | -99.3% |
| FY2022 | 2022-12-31 | 4.58K | +81.8% |
| FY2021 | 2021-12-31 | 2.52K | — |
Common Stock vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 common stock of $2K is the 3rd highest of the 7 companies compared; the peer median is $2K.
- Common stock amounts to 0.0% of total assets for TENX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $8K | +754.7% | -2.2% | 0.0% | |
| Jun 2026 | $4.72K | +575.7% | +100.9% | 0.0% | |
| Mar 2026 | $2K | — | -39.8% | 0.0% | |
| Mar 2026 | $2K | +0.0% | -30.7% | 0.0% | |
| Mar 2026 | $2K | -77.8% | -20.6% | 0.0% | |
| Mar 2026 | $2K | +0.0% | +0.0% | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TENX) | $2K | +0.0% | -2.2% | 0.0% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.